The BCG white paper highlights that digital therapeutics (DTx) promise better access, lower costs, and improved outcomes but face major monetization hurdles. Traditional reimbursement is slow, requiring strong evidence and payer trust. Alternative models include direct-to-consumer apps (subscriptions, freemium), employer partnerships offering DTx as HR benefits, and pharma collaborations to boost adherence. Connected device tie-ins and real-world evidence also create opportunities, while data monetization is emerging as a longer-term strategy. Despite progress like new billing codes and Medicaid coverage for some products, sustainable revenue remains difficult. Success will depend on creative go-to-market models while building payer adoption pathways.

Join for free to read